38941-29-6

Basic information

• Product Name: 4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine
• Synonyms: 4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine
• CAS NO: 38941-29-6
• Molecular Weight: 189.26
• Mol File: 38941-29-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine(38941-29-6)
• EPA Substance Registry System: 4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine(38941-29-6)

Safety Data

• Hazardous Substances Data: 38941-29-6(Hazardous Substances Data)

Usage

General Description

4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amine is a chemical compound with the molecular formula C12H16N2. It is an imidazole derivative with a 2-amino group attached to the second carbon in the imidazole ring. The compound also contains a methylphenylmethyl group attached to the nitrogen atom. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals due to its versatile reactivity. Additionally, it has potential pharmacological properties and could be used as a starting material in drug discovery and development. However, further research is needed to fully understand its biological and chemical properties.

Upstream product

• 96-45-7 N,N'-ethylenethiourea 
• 20112-79-2 2-methylthioimidazoline 
• 89-93-0 ortho-methylbenzylamine 
• 74-88-4 methyl iodide 
• 60546-77-2 methyl 2-(methylthio)-4,5-dihydro-1H-imidazole-1-carboxylate 

Downstream Products

• 1616632-77-9 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetraazatricyclo[7.4.0.0^2,6]trideca-1⁽⁹⁾,5-dien-8-one 

Relevant articles and documents

Imidazo-pyrimidone Compounds, and Preparation Method and Application Thereof

Compounds of formula (I), imidazopyrimidine ketones, as well as preparations and applications thereof. Compounds and pharmaceutically acceptable salts thereof which stimulate the body to produce tumor necrosis factor-related apoptosis-inducing ligands, while avoiding the drawbacks of existing cancer treatments based on recombinant proteins and antibodies. Thus, they can provide novel options for the treatment of related tumors.

PHARMACOPHORE FOR TRAIL INDUCTION

There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidin

METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also use